39 - Biobanques

Service description

Implementation of a regulatory clinical phase for a new drug or repositioning for COVID-19: Phase I for toxicity, Phase IIa or IIb, measurement of efficacy and toxicity on a larger cohort, collection of PK/PD pharmacodynamic data.

It also applies for samples collections that require a specific protocol.

This service is designed for Biotech companies developing SARS-CoV-2 new drugs.

Materials to provide

  • Details about the drug development project

    Further details on the project may be requested.

You will be able to exchange directly with the experts after filling in the form below.

Typical deliverables

  • Study following the specifications validated with the Expert

Get started with your COVID-19 clinical study information request

Please answer the fields below to be contacted by our team of scientists

section1-3
Back
home